| CPC A61K 35/19 (2013.01) [A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 47/6901 (2017.08); C12N 5/0607 (2013.01); C12N 5/0644 (2013.01); C12N 5/0696 (2013.01); C12N 2501/115 (2013.01); C12N 2501/125 (2013.01); C12N 2501/145 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/26 (2013.01); C12N 2501/415 (2013.01); C12N 2501/91 (2013.01); C12N 2506/03 (2013.01); C12N 2506/45 (2013.01); C12N 2513/00 (2013.01); C12N 2533/52 (2013.01)] | 20 Claims |

|
1. A method for differentiating induced pluripotent stem cells (iPSC) to prepare a composition, the method comprising:
expanding induced pluripotent cells in a matrix independent culture using single cell passaging;
dissociating the expanded pluripotent cells into a single cell suspension;
differentiating the dissociated pluripotent cells in a first culture medium into hemogenic endothelial cells;
differentiating the hemogenic endothelial cells in a second culture medium into megakaryocytic progenitors;
differentiating the megakaryocytic progenitors in a third culture medium into megakaryocytes; and
lysing the megakaryocytes so as to obtain a lysate composition comprising one or more of Interleukin 1-beta, Interleukin 16, Interleukin 12P40, TNF-beta, BCA-1, IP-30, Fractalkine, GCkine, MCP-4, MIP-1alpha, MIP-1beta, SDF-1alpha, SDF-1beta, or a combination thereof.
|